Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma.
bioinformatic analysis
bromodomain-containing proteins
epigenetic modification
histone modification regulators
ovarian serous cystadenocarcinoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
08
2022
accepted:
15
09
2022
entrez:
24
10
2022
pubmed:
25
10
2022
medline:
25
10
2022
Statut:
epublish
Résumé
Ovarian serous cystadenocarcinoma (OSC), a common gynecologic tumor, is characterized by high mortality worldwide. Bromodomain (BRD)-containing proteins are a series of evolutionarily conserved proteins that bind to acetylated Lys residues of histones to regulate the transcription of multiple genes. The ectopic expression of BRDs is often observed in multiple cancer types, but the role of BRDs in OSC is still unclear. We performed the differential expression, GO enrichment, GSEA, immune infiltration, risk model, subtype classification, stemness feature, DNA alteration, and epigenetic modification analysis for these BRDs based on multiple public databases. Most BRDs were dysregulated in OSC tissues compared to normal ovary tissues. These BRDs were positively correlated with each other in OSC patients. Gene alteration and epigenetic modification were significant for the dysregulation of BRDs in OSC patients. GO enrichment suggested that BRDs played key roles in histone acetylation, viral carcinogenesis, and transcription coactivator activity. Two molecular subtypes were classified by BRDs for OSC, which were significantly correlated with stemness features, m6A methylation, ferroptosis, drug sensitivity, and immune infiltration. The risk model constructed by LASSO regression with BRDs performed moderately well in prognostic predictions for OSC patients. Moreover, BRPF1 plays a significant role in these BRDs for the development and progression of OSC patients. BRDs are potential targets and biomarkers for OSC patients, especially BRPF1.
Sections du résumé
Background
UNASSIGNED
Ovarian serous cystadenocarcinoma (OSC), a common gynecologic tumor, is characterized by high mortality worldwide. Bromodomain (BRD)-containing proteins are a series of evolutionarily conserved proteins that bind to acetylated Lys residues of histones to regulate the transcription of multiple genes. The ectopic expression of BRDs is often observed in multiple cancer types, but the role of BRDs in OSC is still unclear.
Methods
UNASSIGNED
We performed the differential expression, GO enrichment, GSEA, immune infiltration, risk model, subtype classification, stemness feature, DNA alteration, and epigenetic modification analysis for these BRDs based on multiple public databases.
Results
UNASSIGNED
Most BRDs were dysregulated in OSC tissues compared to normal ovary tissues. These BRDs were positively correlated with each other in OSC patients. Gene alteration and epigenetic modification were significant for the dysregulation of BRDs in OSC patients. GO enrichment suggested that BRDs played key roles in histone acetylation, viral carcinogenesis, and transcription coactivator activity. Two molecular subtypes were classified by BRDs for OSC, which were significantly correlated with stemness features, m6A methylation, ferroptosis, drug sensitivity, and immune infiltration. The risk model constructed by LASSO regression with BRDs performed moderately well in prognostic predictions for OSC patients. Moreover, BRPF1 plays a significant role in these BRDs for the development and progression of OSC patients.
Conclusion
UNASSIGNED
BRDs are potential targets and biomarkers for OSC patients, especially BRPF1.
Identifiants
pubmed: 36276071
doi: 10.3389/fonc.2022.1021558
pmc: PMC9579433
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1021558Informations de copyright
Copyright © 2022 Zhang, Li, Fan, Liu, Zou, Li and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cell Biol. 2015 Jan 5;208(1):53-69
pubmed: 25547156
Nat Struct Mol Biol. 2006 Jan;13(1):22-9
pubmed: 16341228
Nat Cell Biol. 2009 Aug;11(8):1010-6
pubmed: 19578370
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
Nucleic Acids Res. 2018 Jan 4;46(D1):D956-D963
pubmed: 29136207
Nat Rev Cancer. 2012 Jun 22;12(7):465-77
pubmed: 22722403
Urol Oncol. 2019 Sep;37(9):576.e1-576.e10
pubmed: 31178279
Stem Cell Reports. 2015 Dec 8;5(6):971-978
pubmed: 26549848
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211039678
pubmed: 34482774
Aging (Albany NY). 2021 Jan 10;13(3):4045-4062
pubmed: 33428593
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Oncogene. 2000 Mar 16;19(12):1538-46
pubmed: 10734313
Nature. 2010 Dec 16;468(7326):927-32
pubmed: 21164480
Cell Death Dis. 2021 Apr 28;12(5):419
pubmed: 33911074
Curr Opin Drug Discov Devel. 2009 Sep;12(5):659-65
pubmed: 19736624
Commun Biol. 2021 Jul 20;4(1):888
pubmed: 34285329
Genes Dev. 2015 Jan 15;29(2):197-211
pubmed: 25593309
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Breast Cancer Res Treat. 2018 Nov;172(2):339-351
pubmed: 30132219
Nat Struct Mol Biol. 2019 Oct;26(10):870-879
pubmed: 31582847
Front Oncol. 2022 Jul 28;12:968547
pubmed: 35965498
Mol Med Rep. 2020 Aug;22(2):1507-1517
pubmed: 32627014
Genomics. 2000 Jan 1;63(1):40-5
pubmed: 10662543
Nature. 1996 Jul 25;382(6589):319-24
pubmed: 8684459
Cancers (Basel). 2020 Feb 22;12(2):
pubmed: 32098402
Cancer Res. 2009 Nov 1;69(21):8491-8
pubmed: 19843847
Signal Transduct Target Ther. 2021 Jan 11;6(1):10
pubmed: 33431788
J Pers Med. 2022 Jun 17;12(6):
pubmed: 35743773
Gynecol Oncol. 2020 Nov;159(2):546-553
pubmed: 32951893
Proc Natl Acad Sci U S A. 2011 May 31;108(22):E159-68
pubmed: 21536911
Free Radic Biol Med. 2022 May 1;184:135-147
pubmed: 35381326
Development. 2008 Jun;135(11):1935-46
pubmed: 18469222
Clin Cancer Res. 2018 Sep 1;24(17):4119-4125
pubmed: 29776954
Nature. 2013 Jun 13;498(7453):246-50
pubmed: 23728299
Mol Cell. 2002 Nov;10(5):1107-17
pubmed: 12453418
Nucleic Acids Res. 2008 Sep;36(16):5250-9
pubmed: 18684994
Tumour Biol. 2016 Nov;37(11):14803-14812
pubmed: 27638829
Genome Biol. 2003;4(5):P3
pubmed: 12734009
Prostate Cancer Prostatic Dis. 2021 Mar;24(1):268-277
pubmed: 32690869
Cancer Manag Res. 2019 Aug 06;11:7455-7472
pubmed: 31496804
J Hematol Oncol. 2020 Aug 10;13(1):110
pubmed: 32778143
EMBO J. 2016 Jan 18;35(2):176-92
pubmed: 26620551
J Biol Chem. 2006 Jun 16;281(24):16264-71
pubmed: 16603771
Nature. 2005 Aug 11;436(7052):871-5
pubmed: 16094372
EMBO J. 2000 Jul 3;19(13):3377-87
pubmed: 10880450
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Cell. 2005 Apr 8;121(1):87-99
pubmed: 15820681
Nat Genet. 2014 Oct;46(10):1097-102
pubmed: 25151357
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):
pubmed: 35105803
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Trends Biochem Sci. 2015 Aug;40(8):468-79
pubmed: 26145250
Trends Immunol. 2020 Jul;41(7):572-585
pubmed: 32386862
Oncogene. 2005 Jan 27;24(5):916-31
pubmed: 15592518
Dev Growth Differ. 2010 Dec;52(9):747-55
pubmed: 21158754
Nature. 2019 May;569(7755):270-274
pubmed: 31043744
Nature. 2011 Feb 10;470(7333):279-83
pubmed: 21160473
FEBS Lett. 2018 Dec;592(23):3819-3834
pubmed: 30207383
J Biol Chem. 2003 Oct 31;278(44):42733-6
pubmed: 12963728
Biochem Pharmacol. 2004 Sep 15;68(6):1145-55
pubmed: 15313412
EMBO J. 2000 Aug 1;19(15):4123-33
pubmed: 10921892
Mol Cell Biol. 2000 Aug;20(16):6138-46
pubmed: 10913195
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Nat Rev Mol Cell Biol. 2017 Apr;18(4):246-262
pubmed: 28053347
Cell Death Discov. 2020 Nov 10;6(1):119
pubmed: 33298848
J Biol Chem. 2004 Nov 12;279(46):48329-41
pubmed: 15322135
Nature. 2006 Jul 6;442(7098):91-5
pubmed: 16728978
EMBO J. 2012 Oct 3;31(19):3809-20
pubmed: 22922464
Blood. 2011 Sep 1;118(9):2443-53
pubmed: 21753189
Biochem Biophys Res Commun. 2020 Mar 19;523(4):916-923
pubmed: 31959473
Oncogene. 2021 Apr;40(15):2711-2724
pubmed: 33712705
Int J Hematol. 2014 Jan;99(1):21-31
pubmed: 24258712
Mol Cell. 2008 Apr 11;30(1):51-60
pubmed: 18406326
Aging (Albany NY). 2020 Sep 14;12(17):17541-17567
pubmed: 32927435
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13015-20
pubmed: 11078522
Mol Cell. 2014 Jun 5;54(5):728-36
pubmed: 24905006
J Biol Chem. 2008 Nov 21;283(47):32254-63
pubmed: 18809673
Cell. 2020 Jan 23;180(2):387-402.e16
pubmed: 31978347
Mol Cancer Res. 2018 Apr;16(4):610-622
pubmed: 29453316
Mol Cancer Res. 2019 Aug;17(8):1627-1638
pubmed: 31110158
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Expert Rev Mol Med. 2011 Sep 13;13:e29
pubmed: 21933453
Mol Cell Biol. 2007 Sep;27(18):6484-96
pubmed: 17636024
Hum Mol Genet. 2002 Sep 15;11(19):2341-6
pubmed: 12217962
Nat Genet. 2013 Jun;45(6):592-601
pubmed: 23644491
Int J Cancer. 2022 Jun 1;150(11):1838-1849
pubmed: 35049055
Nat Methods. 2014 Jul;11(7):703-4
pubmed: 24972168
Cell Rep. 2019 Dec 17;29(12):4036-4052.e10
pubmed: 31851932
Sci Rep. 2019 Apr 5;9(1):5734
pubmed: 30952871
J Cell Physiol. 2018 Mar;233(3):1877-1886
pubmed: 28500727
Cancer Microenviron. 2019 Dec;12(2-3):181-195
pubmed: 31267484
Aging (Albany NY). 2020 Feb 3;12(3):2132-2141
pubmed: 32012118